Summary
Delivery to diseased cells or tissues of therapeutic agents attached or encapsulated in nanoparticles – nanomedicine - presents many benefits, and comprises a rapidly-growing multi-billion-euro market. Lipid-based drug-delivery nano-vehicles, where drugs (not least the recent, very-widely-used, mRNA-based COVID-19 vaccines) are encapsulated in lipid vesicles (liposomes) or lipid nanoparticles, form a substantial part of that market. Nearly all FDA-approved liposomic vehicles are functionalized with poly(ethylene glycol), PEG, moieties, the current gold-standard. These act both to sterically-stabilize the vesicles, and, importantly, increase their blood-retention time and thus their therapeutic efficiency. At the same time, such PEGylation has several drawbacks, including reduced cellular uptake, accumulation of PEG in tissues, and accelerated blood clearance on repeated intravenous dosage due to heightened immune response. We use novel functionalization approaches to overcome these drawbacks. The present project explores the innovation dimension of our new approach. In particular, is it effective? is it efficient? How widely applicable is it? What is the IPR position for future exploitation of this new strategy? These questions illustrate the high-risk/high-gain nature of this proposal, and are addressed here through several inter-related work packages. Success of our project in demonstrating that our novel approach is significantly superior to the current universally-used PEGylation would not only have a therapeutic advantage for many diseases, but also tap into a large and growing market.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101082135 |
| Start date: | 01-02-2023 |
| End date: | 31-07-2024 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
Delivery to diseased cells or tissues of therapeutic agents attached or encapsulated in nanoparticles – nanomedicine - presents many benefits, and comprises a rapidly-growing multi-billion-euro market. Lipid-based drug-delivery nano-vehicles, where drugs (not least the recent, very-widely-used, mRNA-based COVID-19 vaccines) are encapsulated in lipid vesicles (liposomes) or lipid nanoparticles, form a substantial part of that market. Nearly all FDA-approved liposomic vehicles are functionalized with poly(ethylene glycol), PEG, moieties, the current gold-standard. These act both to sterically-stabilize the vesicles, and, importantly, increase their blood-retention time and thus their therapeutic efficiency. At the same time, such PEGylation has several drawbacks, including reduced cellular uptake, accumulation of PEG in tissues, and accelerated blood clearance on repeated intravenous dosage due to heightened immune response. We use novel functionalization approaches to overcome these drawbacks. The present project explores the innovation dimension of our new approach. In particular, is it effective? is it efficient? How widely applicable is it? What is the IPR position for future exploitation of this new strategy? These questions illustrate the high-risk/high-gain nature of this proposal, and are addressed here through several inter-related work packages. Success of our project in demonstrating that our novel approach is significantly superior to the current universally-used PEGylation would not only have a therapeutic advantage for many diseases, but also tap into a large and growing market.Status
SIGNEDCall topic
ERC-2022-POC2Update Date
12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
